Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule

Inclusion Criteria: * Two-month old infants of either gender on the day of inclusion * Born at full term of pregnancy (\>=37 weeks) with a birth weight \>=2.5 kg * Informed consent form signed by the parent(s) or other legal representative(s) and an institution official other than an investigator * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Participation in another clinical trial in the 4 weeks preceding the first trial vaccination * Planned participation in another clinical trial during the present trial period * Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroid therapy * Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to a vaccine containing the same substances * Chronic illness at a stage that could interfere with trial conduct or completion * Blood or blood-derived products received since birth * Any vaccination (except BCG) in the 4 weeks preceding the first trial vaccination * Vaccination planned in the 4 weeks following trial vaccination * History of documented pertussis, tetanus, diphtheria, polio, Haemophilus influenzae type b or hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically) * Known personal or maternal history of HIV, Hepatitis B or Hepatitis C seropositivity * Previous vaccination against pertussis, tetanus, diphtheria, polio or Hib, and HB infection(s) * Coagulopathy, thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination * History of seizures * Febrile (axillary temperature 37.4°C \[rectal equivalent temperature \>=38.0°C\]) or acute illness on the day of inclusion.